| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 17 | 2018 | 473 | 1.420 |
Why?
|
| Cancer Vaccines | 5 | 2020 | 159 | 1.230 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2019 | 232 | 1.080 |
Why?
|
| Receptors, Antigen, T-Cell | 11 | 2022 | 406 | 0.950 |
Why?
|
| T-Lymphocytes | 9 | 2019 | 1228 | 0.940 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2014 | 147 | 0.910 |
Why?
|
| MART-1 Antigen | 4 | 2018 | 21 | 0.710 |
Why?
|
| Immunotherapy | 5 | 2020 | 703 | 0.690 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 776 | 0.630 |
Why?
|
| Dendritic Cells | 4 | 2023 | 451 | 0.610 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 601 | 0.570 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 478 | 0.540 |
Why?
|
| Indoles | 7 | 2014 | 306 | 0.520 |
Why?
|
| Antibodies, Monoclonal | 5 | 2015 | 1397 | 0.520 |
Why?
|
| Immunotherapy, Active | 2 | 2015 | 15 | 0.510 |
Why?
|
| Sulfonamides | 6 | 2014 | 320 | 0.480 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 135 | 0.460 |
Why?
|
| Skin Neoplasms | 6 | 2018 | 600 | 0.450 |
Why?
|
| Antineoplastic Agents | 7 | 2016 | 2337 | 0.450 |
Why?
|
| Lymphocytes | 3 | 2014 | 470 | 0.430 |
Why?
|
| Antigens, Neoplasm | 4 | 2022 | 335 | 0.360 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 452 | 0.330 |
Why?
|
| Neoplasms | 4 | 2022 | 3029 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2018 | 320 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 610 | 0.250 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2019 | 277 | 0.250 |
Why?
|
| Keloid | 2 | 2003 | 8 | 0.240 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2023 | 112 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2014 | 226 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 333 | 0.220 |
Why?
|
| Carbonic Anhydrase IX | 2 | 2020 | 11 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2013 | 589 | 0.200 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2022 | 23 | 0.200 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 525 | 0.200 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 340 | 0.200 |
Why?
|
| Genetic Therapy | 3 | 2015 | 373 | 0.200 |
Why?
|
| Receptors, CXCR6 | 1 | 2021 | 6 | 0.190 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 17 | 0.190 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 59 | 0.190 |
Why?
|
| Fibroblasts | 2 | 2003 | 764 | 0.190 |
Why?
|
| Humans | 34 | 2023 | 90568 | 0.190 |
Why?
|
| Autocrine Communication | 1 | 2000 | 21 | 0.180 |
Why?
|
| Transduction, Genetic | 4 | 2014 | 160 | 0.180 |
Why?
|
| fas Receptor | 1 | 2000 | 77 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2010 | 467 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 337 | 0.160 |
Why?
|
| Apoptosis | 3 | 2014 | 1723 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2003 | 326 | 0.160 |
Why?
|
| Cells, Cultured | 6 | 2018 | 2892 | 0.160 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 2607 | 0.160 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2019 | 10 | 0.160 |
Why?
|
| CTLA-4 Antigen | 3 | 2014 | 140 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2016 | 962 | 0.150 |
Why?
|
| Lymphocyte Activation | 6 | 2022 | 756 | 0.140 |
Why?
|
| Female | 17 | 2022 | 46855 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 914 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 1066 | 0.130 |
Why?
|
| Cell Survival | 3 | 2019 | 987 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 269 | 0.130 |
Why?
|
| Cell Cycle | 2 | 2015 | 511 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 342 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 354 | 0.120 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 3 | 0.120 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 99 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1708 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2014 | 465 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 538 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 46 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 103 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2014 | 3426 | 0.100 |
Why?
|
| Carbonic Anhydrases | 1 | 2013 | 15 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 309 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 279 | 0.100 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 245 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2010 | 135 | 0.100 |
Why?
|
| Vaccination | 1 | 2014 | 280 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2012 | 135 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 2018 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2011 | 25 | 0.090 |
Why?
|
| K562 Cells | 1 | 2010 | 45 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 65 | 0.090 |
Why?
|
| Animals | 8 | 2022 | 27691 | 0.090 |
Why?
|
| Antineoplastic Protocols | 1 | 2010 | 9 | 0.090 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 182 | 0.090 |
Why?
|
| Middle Aged | 10 | 2018 | 26327 | 0.090 |
Why?
|
| Mice | 7 | 2022 | 11932 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 106 | 0.090 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 22 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2020 | 8373 | 0.090 |
Why?
|
| Genes, ras | 1 | 2010 | 97 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 413 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1688 | 0.090 |
Why?
|
| Epitopes | 1 | 2010 | 254 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 198 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 159 | 0.080 |
Why?
|
| Male | 12 | 2018 | 42931 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2010 | 145 | 0.080 |
Why?
|
| Adult | 9 | 2018 | 26940 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 207 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1286 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1935 | 0.070 |
Why?
|
| Antibodies | 2 | 2013 | 353 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2010 | 697 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2018 | 218 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2003 | 89 | 0.060 |
Why?
|
| Aged | 7 | 2018 | 19404 | 0.060 |
Why?
|
| Caspases | 2 | 2002 | 155 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2702 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 194 | 0.050 |
Why?
|
| Gelsolin | 1 | 2002 | 11 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2003 | 146 | 0.050 |
Why?
|
| Cell Communication | 1 | 2003 | 201 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2013 | 26 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2023 | 351 | 0.050 |
Why?
|
| Granzymes | 1 | 2022 | 95 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2023 | 345 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 88 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 97 | 0.050 |
Why?
|
| Staurosporine | 1 | 2000 | 33 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2000 | 53 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 46 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2013 | 660 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2000 | 233 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2014 | 176 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 872 | 0.040 |
Why?
|
| Cytokines | 2 | 2014 | 813 | 0.040 |
Why?
|
| Phenotype | 2 | 2018 | 2471 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 332 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2018 | 71 | 0.040 |
Why?
|
| Base Sequence | 2 | 2012 | 2329 | 0.040 |
Why?
|
| Mutation | 3 | 2014 | 4184 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2018 | 165 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 665 | 0.030 |
Why?
|
| Cell Line | 2 | 2012 | 2505 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2033 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2407 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 6812 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2030 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2010 | 728 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 174 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2002 | 1550 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2014 | 25 | 0.030 |
Why?
|
| Oximes | 1 | 2013 | 16 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 161 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 50 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2013 | 16 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 2523 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2013 | 3 | 0.030 |
Why?
|
| Chemokine CCL1 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2013 | 52 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 138 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 179 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 372 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 131 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 138 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 446 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 166 | 0.030 |
Why?
|
| Proteome | 1 | 2014 | 139 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 86 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2013 | 147 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 261 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 166 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 39 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 162 | 0.020 |
Why?
|
| DNA Damage | 1 | 2014 | 374 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 123 | 0.020 |
Why?
|
| Microchip Analytical Procedures | 1 | 2011 | 3 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2012 | 111 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 289 | 0.020 |
Why?
|
| Exome | 1 | 2012 | 131 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 107 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 180 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Monophenol Monooxygenase | 1 | 2010 | 9 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 43 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 38 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 1049 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 552 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 1095 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 200 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 98 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 293 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 198 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 274 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 295 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2010 | 116 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2009 | 38 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 202 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 694 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 997 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1312 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 693 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 105 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1583 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 374 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 561 | 0.020 |
Why?
|
| Macrophages | 1 | 2011 | 585 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 172 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1231 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1550 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1382 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3273 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2003 | 33 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 103 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 112 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2002 | 34 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2002 | 49 | 0.010 |
Why?
|
| Mesentery | 1 | 2002 | 45 | 0.010 |
Why?
|
| Nevus, Pigmented | 1 | 2002 | 53 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 691 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 794 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1132 | 0.010 |
Why?
|
| Skin | 1 | 2003 | 590 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2076 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 553 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3029 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1357 | 0.010 |
Why?
|
| Child | 1 | 2003 | 7216 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 9353 | 0.010 |
Why?
|